Adiponectin in Acute Coronary Syndrome The National Cardiovascular Center “Harapan Kita” Study
Abstract
Objective.The association of hypoadiponectinemia and the development of obesity-related condition, including dislipidemia and coronary heart dis-ease (CHD) has been known. The results of some studies on hypoadiponectinemia as a predictor of coronary artery disease is still con-troversial. The aim of this study is to examine whether the hypo-adiponectinemia can be used as a predictor of total MACE among patients with acute coronary syndrome (ACS).Patients and methods. This a cohort study recruits 80 patients with Acute Coronary Syndrome in Emergency Department of National Car-diovascular Center Harapan Kita, Jakarta. They were followed for a me-dian follow-up of 81.48 days; the end points are re-infarct, recurrent is-chemia, heart failure and all causes of mortality. The mean age is 54.51 ± 9.02 year. Sixty-three patient is male (78.8%) and 17 is female (21.3%). The mean total cholesterol is 202.14 ± 45.10 mg/dl, mean HDL is 36.75 ± 13.56 mg/dl, mean LDL is 125.42 ± 39.26 mg/dl and mean triglycerides is 182.61 ± 104.40 mg/dl. The most common risk factors are hyperten-sion (51,3%) and smoker (53,8%). The mean adiponectin level is 8.15 ± 3.67 ug/ml. On multivariate analysis, hypoadiponectinemia (< 5.34 ug/ml) tends to associates with total MACE, though statistically insignificant, with RR of 4.33 (95% CI: 0.86 – 21.8; P = 0.075).
Conclusions. These results suggest that hypoadipoadiponectinemia is not significantly associates with total MACE in those ACS patients.
Downloads
Download data is not yet available.
References
Tonkin A. 2004. The metabolic syndrome - a growing problem. Eur Heart J, 6 (Supplemen A): A37-A42.
Pyorala K. 1979. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: Results from two population studies in Finland. Diabetes Care, 2: 131-41.
Lebovitz H.E. 2001. The metabolic syndrome: unresolved issue. In: Schwartz C.L, Born G.V.R, eds. Occlusive Arterial Disease. The Interfaces among Dyslipidemias, Hypertension and Diabetes. Stuttgart: Schattauer. 261-75.
Bacquer DD, De Backer G, Cokkinos D, Keil U, Montayen 6stor E, et.al. 2004. Overweight and obesity in patients with established coronary heart disease: Are we meeting the chalenge? Eur Heart J, 25: 121-128
Nielsen S, Jensen A4D. 1997. Obesity and cardiovascular disease: is body structur a factor? Curr Opin Lipidol, 8: 200-4
Kondo H, Shimomura 1, Matsukawa Y, Kumada M, Takahashi K Matsuda M, et.al. 2002. Brief Genetic Reports. Association of Adiponectin 11Autation With Type-2 Diabetes. A Candidate Gene for the Insulin Resistance Syndrome. Diabetes, 5 1 2325-8
Waki H, Yamauchi T, Kamon J, Ito Y, Uchida S, Kita S, et.al. 2003. Impaired multimerization of Human Adiponectin Mutants Associated Diabetes. J Biol Chemistry, 278(4l): 40352-40363.
Wajchenberg BL. Subcutaneus and visceral adipose tissue : their relation to the metabolic syndrome. Endocrine Reviews 21(6):697-738, 2000
Stejskal David, et al. 2003, Adiponectin in Patients with Various Stagesof Coronary Heart Disease – Comparison of Its Concentration in Coronary Arteries And Peripheral Venous Circulation. Biomed Papers 147(2), 161-166
Lindsay S et al. 2005. Adiponectin and Coronary Heart Disease: The Strong Heart Study. Arterioscler. Thromb. Vasc. Biol. 25;15-16
Gail A. Laughlin, et al. 2006. Association of Adiponectin with Coronary Heart Disease and Mortality-The Rancho Bernardo Study. American Journal of Epidemiology, Vol 165, No 2.
Sattar N, et al. 2006. Adiponectin and Coronary Heart Disease: A Prospective Study and Meta-AnalysisCirculation ;114;623-629;
Ouchi N, Kiliara S, Funahashi T, Matsuzawa Y, Walsh K. 2003. Obesity, adiponectin and vascular inflammatory disease. Curr Opinion in Lipidol, 14: 561-566.
Blake GJ, Ridker PM. 2001. Novel clinical markers of vascular inflammation. Circ Res, 89.. 763-771
Engeli S, Feldpausch M, Gorzelniak K, Hartwig F, Heintze U, Janke J, et al. 2003. Association Between Adiponectin and Mediators of Inflammation in Obese Women. Diabetes, 52: 942-947
Krakoff J, Funahashi T, Stehouwer CD. 2003. Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes Care, 26: 1745-175 1
Esposito K, Pontillo A, Di Pallo C. 2003. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA, 289: 1799-1804
Fasshauer K Kralisch S, Klier M. 2003. Adiponectin gene expression and secretion is inhibited by interleukin-6 in M-LI adipocytes. Biochem Biophys Res Commun, 301: 1045-1050
Santoso A, 2005. Hipoadiponektinemia Sebagai Faktor Risiko Infark Miokard Akut Melalui Peningkatan Konsentrasi s-ICAM Dan TNF-aPlasma.
Pyorala K. 1979. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: Results from two population studies in Finland. Diabetes Care, 2: 131-41.
Lebovitz H.E. 2001. The metabolic syndrome: unresolved issue. In: Schwartz C.L, Born G.V.R, eds. Occlusive Arterial Disease. The Interfaces among Dyslipidemias, Hypertension and Diabetes. Stuttgart: Schattauer. 261-75.
Bacquer DD, De Backer G, Cokkinos D, Keil U, Montayen 6stor E, et.al. 2004. Overweight and obesity in patients with established coronary heart disease: Are we meeting the chalenge? Eur Heart J, 25: 121-128
Nielsen S, Jensen A4D. 1997. Obesity and cardiovascular disease: is body structur a factor? Curr Opin Lipidol, 8: 200-4
Kondo H, Shimomura 1, Matsukawa Y, Kumada M, Takahashi K Matsuda M, et.al. 2002. Brief Genetic Reports. Association of Adiponectin 11Autation With Type-2 Diabetes. A Candidate Gene for the Insulin Resistance Syndrome. Diabetes, 5 1 2325-8
Waki H, Yamauchi T, Kamon J, Ito Y, Uchida S, Kita S, et.al. 2003. Impaired multimerization of Human Adiponectin Mutants Associated Diabetes. J Biol Chemistry, 278(4l): 40352-40363.
Wajchenberg BL. Subcutaneus and visceral adipose tissue : their relation to the metabolic syndrome. Endocrine Reviews 21(6):697-738, 2000
Stejskal David, et al. 2003, Adiponectin in Patients with Various Stagesof Coronary Heart Disease – Comparison of Its Concentration in Coronary Arteries And Peripheral Venous Circulation. Biomed Papers 147(2), 161-166
Lindsay S et al. 2005. Adiponectin and Coronary Heart Disease: The Strong Heart Study. Arterioscler. Thromb. Vasc. Biol. 25;15-16
Gail A. Laughlin, et al. 2006. Association of Adiponectin with Coronary Heart Disease and Mortality-The Rancho Bernardo Study. American Journal of Epidemiology, Vol 165, No 2.
Sattar N, et al. 2006. Adiponectin and Coronary Heart Disease: A Prospective Study and Meta-AnalysisCirculation ;114;623-629;
Ouchi N, Kiliara S, Funahashi T, Matsuzawa Y, Walsh K. 2003. Obesity, adiponectin and vascular inflammatory disease. Curr Opinion in Lipidol, 14: 561-566.
Blake GJ, Ridker PM. 2001. Novel clinical markers of vascular inflammation. Circ Res, 89.. 763-771
Engeli S, Feldpausch M, Gorzelniak K, Hartwig F, Heintze U, Janke J, et al. 2003. Association Between Adiponectin and Mediators of Inflammation in Obese Women. Diabetes, 52: 942-947
Krakoff J, Funahashi T, Stehouwer CD. 2003. Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian. Diabetes Care, 26: 1745-175 1
Esposito K, Pontillo A, Di Pallo C. 2003. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA, 289: 1799-1804
Fasshauer K Kralisch S, Klier M. 2003. Adiponectin gene expression and secretion is inhibited by interleukin-6 in M-LI adipocytes. Biochem Biophys Res Commun, 301: 1045-1050
Santoso A, 2005. Hipoadiponektinemia Sebagai Faktor Risiko Infark Miokard Akut Melalui Peningkatan Konsentrasi s-ICAM Dan TNF-aPlasma.
Views & Downloads
Abstract views: 3421
PDF (Bahasa Indonesia) downloads: 2508
PDF (Bahasa Indonesia) downloads: 2508
How to Cite
Pradnyana, B., Hersunarti, N., & Karo Karo, S. (1). Adiponectin in Acute Coronary Syndrome The National Cardiovascular Center “Harapan Kita” Study. Indonesian Journal of Cardiology, 28(6), 431-437. https://doi.org/10.30701/ijc.v28i6.209
Section
Clinical Research
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
